Figure 4

Therapeutic siRNA delivered using SNALP exhibits better efficacy against highly vascularized tumors. (a) HepG2 and HCT116 cells were used to create liver tumors in scid mice via intrahepatic inoculation. At 72 h after inoculation, mice were either untreated or administrated with empty SNALP liposome, SNALP liposomes containing NTC or siRNA-targeting Ran (siRAN; intravenous, 2.5 mg siRNA kg⁻¹, twice per week) for 3 weeks. Tumor weight in each mouse was determined 72 h after the last dosing. %T/C (the ratio between the mean tumor weight of treated mice (T) and that of control mice (C)) was calculated as the average tumor weight in treated mice versus the average tumor weight in untreated group. N=15 for each treatment group, and the average %T/C ±s.e.m. was plotted. (b) HCT116 and HepG2 cells were incubated with different amounts of SNALP containing a NTC or siRAN, and the number of viable cells was determined 72 h later using the CellTiter Glo kit.